DEDIFFERENTIATED LIPOSARCOMA
Clinical trials for DEDIFFERENTIATED LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new DEDIFFERENTIATED LIPOSARCOMA trials appear
Sign up with your email to follow new studies for DEDIFFERENTIATED LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new oral drug called STC-15, either alone or combined with toripalimab, in people with advanced solid tumors or certain sarcomas (leiomyosarcoma and liposarcoma). The goal is to see if the treatment is safe and can shrink or control tumors. About 107 adults wit…
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: STORM Therapeutics LTD • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New combo therapy aims to halt rare cancer growth
Disease control Recruiting nowThis study tests whether two drugs, mirdametinib and palbociclib, can safely control advanced liposarcoma that has spread or cannot be removed by surgery. About 54 adults with this rare cancer will receive different doses to find the best balance of safety and effectiveness. The …
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control
Last updated May 13, 2026 16:03 UTC